Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02JMI
|
||||
Former ID |
DCL000988
|
||||
Drug Name |
SLV-310
|
||||
Synonyms |
L001635; 2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]isoindole-1,3-dione
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Discontinued in Phase 2 | [1] | ||
Company |
Solvay Pharma
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C25H24FN3O2
|
||||
Canonical SMILES |
C1CN(CC=C1C2=CNC3=C2C=C(C=C3)F)CCCCN4C(=O)C5=CC=CC=C5C4<br />=O
|
||||
InChI |
1S/C25H24FN3O2/c26-18-7-8-23-21(15-18)22(16-27-23)17-9-13-28(14-10-17)11-3-4-12-29-24(30)19-5-1-2-6-20(19)25(29)31/h1-2,5-9,15-16,27H,3-4,10-14H2
|
||||
InChIKey |
NECJNLXOJRDELU-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | D(2) dopamine receptor | Target Info | Modulator | ||
KEGG Pathway | Rap1 signaling pathway | ||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Dopaminergic synapse | |||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Dopamine receptor mediated signaling pathway | |||||
Nicotine pharmacodynamics pathway | |||||
Reactome | Dopamine receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Genes and (Common) Pathways Underlying Drug Addiction | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
Nicotine Activity on Dopaminergic Neurons | |||||
References | |||||
REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.